Exelixis, Inc. (LON:0IJO)

Market Cap	9.15B
Revenue (ttm)	1.78B
Net Income (ttm)	498.11M
Shares Out	n/a
EPS (ttm)	1.71
PE Ratio	18.37
Forward PE	16.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,005
Average Volume	2,601
Open	44.64
Previous Close	43.82
Day's Range	43.95 - 45.15
52-Week Range	21.90 - 51.98
Beta	n/a
RSI	65.53
Earnings Date	Aug 5, 2025

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1994
• Employees: 1,147
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IJO

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD